COMPANY PROFILE

Idience

Explore full profile

Precision Medicine, Idea into Science, Biopharmaceutical

Seoul, South KoreaHealth

Valuation $25–50M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Idience

Idience is a science-driven biopharmaceutical company focused on improving the quality of life for oncology patients. Operating in the biopharmaceutical sector, Idience specializes in the development of PARP inhibitors, which are a class of drugs used in cancer treatment. The company serves patients, healthcare providers, and research institutions by conducting clinical trials and developing innovative therapies aimed at combating cancer. Idience's business model revolves around extensive research and development (R&D), clinical trials, and eventual commercialization of its proprietary drugs. Revenue is primarily generated through the sale of these specialized oncology medications and potential partnerships or licensing agreements with larger pharmaceutical companies. The company is headquartered in San Francisco, California, and is committed to transforming scientific discoveries into practical medical solutions.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Headquarters: Seoul, South Korea
Employees: 12
Open positions: None listed
Dealroom signal: 0.0/100
Industry: Health
Sector: Health, Precision Medicine
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

1 recorded event

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	May 2024	$21M	$84M	Dong-A ST	↗

Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Idience website traffic

Latest recorded traffic for Idience is 2.5K monthly website visits, up 242.5% over the last three months. Idience's team grew 9.1% over the past year.

Latest monthly visits2.5K 3-month web change+242.5% 1-year team growth+9.1%

Monthly website visitsMay 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DCDCDC-TxPrecision therapy development via AI-enhanced pathway profiling	Vught, Netherlands	Operational	—	—	—
MBMerida BiosciencesPrecision immunology leader developing targeted therapies for autoimmune and allergic disorders	Cambridge, United States	Acquired
ATAizen TherapeuticsDevelops AI-driven Mirror Peptides, a novel class of biologic medicines, to treat neurological disorders, cancers, and genetic diseases	San Diego, United States	Operational
THTheremiaLeverage AI for inclusive healthcare	Paris, France	Operational
TATagomicsMultiomic platform for disease biomarker discovery and diagnostics	Cambridge, United Kingdom	Operational
PMPathCision MedicineDeveloping targeted therapies for complex diseases, with a primary focus on metastatic cancer	Watertown, United States	Operational
GHGenomate HealthAI-powered computational tools for personalized oncology treatment	Cambridge, United States	Operational
RARaidiumRaidium foundation model: Radiology augmented GPT to tackle the complexity of precision medicine	Roubaix, France	Operational